MapLight's Lead Drug Nears Key Phase 2 Readouts for Schizophrenia, ADP

TL;DR

**MPLT is a high-risk, clinical-stage biotech with no revenue, betting big on its lead CNS drug ML-007C-MA; expect extreme volatility around Phase 2 data in 2026 and 2027.**

AI Summary

MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company focused on CNS disorders, reporting no commercialized products and a limited operating history for the fiscal year ended December 31, 2025. The company's lead product candidate, ML-007C-MA, a fixed-dose combination for schizophrenia and Alzheimer's disease psychosis (ADP), is currently in Phase 2 trials. The ZEPHYR trial for schizophrenia is expected to enroll 300 participants by April 2026 and report topline results in Q3 2026. The VISTA trial for ADP is anticipated to report topline results in H2 2027. ML-007C-MA received FDA Fast Track designation in December 2025 for hallucinations and delusions associated with ADP. The company has evaluated ML-007 alone or co-formulated in four Phase 1 trials with 270 healthy participants, administering over 1,500 doses of ML-007. MPLT will require substantial additional capital to fund its product development and commercialization efforts, as highlighted in its risk factors.

Why It Matters

MapLight Therapeutics is tackling significant unmet needs in schizophrenia and Alzheimer's disease psychosis, conditions affecting millions globally, including over 3 million people with schizophrenia and 7 million with Alzheimer's in the U.S. Current treatments, primarily dopaminergic antipsychotics, have severe side effects and limited efficacy, especially for negative and cognitive symptoms. MPLT's muscarinic agonist approach, ML-007C-MA, aims to offer a better-tolerated and more effective alternative, potentially disrupting a market where the first novel muscarinic agent, Cobenfy, was recently approved. Success could mean improved quality of life for patients, reduced healthcare burdens, and a substantial return for investors, while failure would leave a critical gap in treatment options and significant financial losses.

Risk Assessment

Risk Level: high — MapLight Therapeutics is a clinical-stage company with no commercialized products and a limited operating history, indicating high inherent risk. The company explicitly states it "will require substantial additional capital to achieve our goals," and failure to secure this funding could terminate product development. Furthermore, clinical development is a lengthy and expensive process with uncertain outcomes, as highlighted by the risk that "results of earlier studies and trials often failing to predict future trial results."

Analyst Insight

Investors should approach MPLT with extreme caution, recognizing it as a speculative bet on clinical trial success. Monitor the upcoming Q3 2026 topline results for the ZEPHYR Phase 2 trial in schizophrenia and the H2 2027 results for the VISTA Phase 2 trial in ADP, as these will be critical catalysts determining the company's future viability and potential need for further capital raises.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$XX,XXX,XXX

total Debt

$0

net Income

$-XX,XXX,XXX

eps

$-X.XX

gross Margin

N/A

cash Position

$XX,XXX,XXX

revenue Growth

N/A

Key Numbers

• 300 — target enrollment for ZEPHYR Phase 2 trial (expected by April 2026)
• 2026 — fiscal year ended (December 31, 2025)
• 42,436,326 — shares of Voting Common Stock outstanding (as of March 19, 2026)
• 270 — healthy participants enrolled in Phase 1 trials (for ML-007)
• 1,500 — doses of ML-007 administered (in Phase 1 trials)
• 20 million — people globally affected by schizophrenia (significant market opportunity)
• 3 million — people in the United States affected by schizophrenia (significant market opportunity)
• 40% — Alzheimer's patients experiencing psychosis (out of 7 million in the US)

Key Players & Entities

• MapLight Therapeutics, Inc. (company) — Registrant
• ML-007C-MA (company) — lead product candidate
• FDA (regulator) — granted Fast Track designation
• Nasdaq Global Select Market (company) — exchange where common stock is registered
• Cobenfy (company) — competitor M1/M4 muscarinic agonist
• ML-007 (company) — M1/M4 muscarinic agonist component
• ML-004 (company) — second product candidate

Forward-Looking Statements

• MapLight Therapeutics, Inc. will continue to operate in the pharmaceutical preparations sector. (MapLight Therapeutics, Inc.) — high confidence, target: 2027-12-31

FAQ

Risk Factors

• Need for substantial additional capital [high — financial]: The company has a limited operating history and no commercialized products. Development of its product candidates, particularly ML-007C-MA, requires significant capital expenditures. MPLT will require substantial additional capital to fund its ongoing research and development activities, clinical trials, and potential commercialization efforts.
• FDA approval uncertainty [high — regulatory]: The company's product candidates are in clinical development and have not yet received regulatory approval. The success of ML-007C-MA is dependent on successful completion of Phase 2 and Phase 3 trials and subsequent FDA approval. There is no guarantee that the company will obtain the necessary regulatory approvals.
• Competition in CNS disorder market [medium — market]: The market for treatments for CNS disorders, including schizophrenia and Alzheimer's disease psychosis, is highly competitive. MPLT faces competition from established pharmaceutical companies and other biotechnology firms developing novel therapies. The success of ML-007C-MA will depend on its ability to demonstrate superior efficacy and safety compared to existing and emerging treatments.
• Reliance on key personnel [medium — operational]: The company's success depends on its ability to attract and retain highly qualified scientific and management personnel. The loss of key personnel could adversely affect its ability to conduct research, develop products, and manage its operations.
• Burn rate and cash runway [high — financial]: As a clinical-stage company with no revenue, MPLT has a significant cash burn rate. The company's ability to continue operations is dependent on its ability to secure additional funding. A prolonged period without sufficient funding could force the company to delay, scale back, or discontinue its development programs.

Industry Context

The biopharmaceutical industry, particularly in the CNS disorder space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like MapLight Therapeutics compete with both large, established pharmaceutical firms and smaller, innovative biotech companies. Key trends include the increasing focus on precision medicine, the development of novel therapeutic modalities, and the growing demand for treatments for neurodegenerative diseases and psychiatric conditions.

Regulatory Implications

MapLight Therapeutics faces significant regulatory risks associated with the development of its drug candidates. The company must successfully navigate the FDA's rigorous clinical trial process and obtain marketing approval for ML-007C-MA. The Fast Track designation provides a potential advantage, but does not guarantee approval. Any delays or setbacks in clinical trials or regulatory reviews could materially impact the company's prospects.

What Investors Should Do

1. Monitor ZEPHYR trial results
2. Assess VISTA trial progress
3. Evaluate funding needs and sources
4. Analyze competitive landscape

Key Dates

• 2025-12-01: FDA Fast Track designation for ML-007C-MA — Accelerates development and potential review of the drug candidate for hallucinations and delusions associated with Alzheimer's disease psychosis.
• 2026-04-01: Target enrollment for ZEPHYR Phase 2 trial — Indicates progress in the clinical development of ML-007C-MA for schizophrenia, with 300 participants expected.
• 2026-07-01: Expected topline results for ZEPHYR trial — Key milestone for assessing the efficacy and safety of ML-007C-MA in schizophrenia patients.
• 2027-07-01: Anticipated topline results for VISTA trial (H2 2027) — Crucial data point for the development of ML-007C-MA in Alzheimer's disease psychosis.

Glossary

Clinical-stage biopharmaceutical company

A company focused on developing new drugs that are currently undergoing testing in human clinical trials, rather than being available for sale. (MPLT is in this stage, meaning its success hinges on successful trial outcomes and regulatory approvals, not current sales.)

CNS disorders

Central Nervous System disorders, affecting the brain and spinal cord, such as schizophrenia and Alzheimer's disease. (This is the therapeutic area MapLight Therapeutics is targeting with its product candidates.)

Fixed-dose combination

A pharmaceutical product containing two or more active drugs in a single dosage form. (ML-007C-MA is a fixed-dose combination, which can simplify treatment regimens for patients.)

FDA Fast Track designation

A process by which the U.S. Food and Drug Administration (FDA) expedites the development and review of drugs intended to treat serious conditions and that demonstrate the potential to address unmet medical needs. (This designation for ML-007C-MA suggests potential for a quicker path to market if clinical data is positive.)

Topline results

The primary results of a clinical trial, typically focusing on the main efficacy and safety endpoints, released shortly after the trial concludes. (These results are critical for investors to assess the progress and potential success of MPLT's drug candidates.)

Year-Over-Year Comparison

As a clinical-stage company, MapLight Therapeutics likely reported minimal to no revenue in its prior filings as well. The primary focus remains on the progression of its drug candidates through clinical trials. Key metrics to compare would be cash position, R&D expenses, and any updates to clinical trial timelines or regulatory milestones, which are expected to show advancement given the current reporting period's updates on trial enrollment and designations.

Key Financial Figures

• $0.0001 — which registered Voting Common Stock, $0.0001 par value per share MPLT Nasdaq Glo

Filing Documents

• mplt-20251231.htm (10-K) — 3261KB
• mplt-ex4_2.htm (EX-4.2) — 61KB
• mplt-ex10_9.htm (EX-10.9) — 25KB
• mplt-ex10_10.htm (EX-10.10) — 23KB
• mplt-ex19_1.htm (EX-19.1) — 127KB
• mplt-ex23_1.htm (EX-23.1) — 6KB
• mplt-ex31_1.htm (EX-31.1) — 18KB
• mplt-ex31_2.htm (EX-31.2) — 18KB
• mplt-ex32_1.htm (EX-32.1) — 9KB
• mplt-ex97_1.htm (EX-97.1) — 50KB
• img188030677_0.jpg (GRAPHIC) — 465KB
• img188030677_1.jpg (GRAPHIC) — 223KB
• img188030677_2.jpg (GRAPHIC) — 68KB
• img188030677_3.jpg (GRAPHIC) — 218KB
• img188030677_4.jpg (GRAPHIC) — 259KB
• img188030677_5.jpg (GRAPHIC) — 161KB
• img188030677_6.jpg (GRAPHIC) — 213KB
• img188030677_7.jpg (GRAPHIC) — 238KB
• img188030677_8.jpg (GRAPHIC) — 213KB
• img188030677_9.jpg (GRAPHIC) — 191KB
• img188030677_10.jpg (GRAPHIC) — 276KB
• img188030677_11.jpg (GRAPHIC) — 321KB
• img253101537_0.gif (GRAPHIC) — 16KB
• img253101537_1.jpg (GRAPHIC) — 60KB
• img253101537_2.jpg (GRAPHIC) — 60KB
• gfx253101537_0.jpg (GRAPHIC) — 2KB
• 0001193125-26-125072.txt ( ) — 19908KB
• mplt-20251231.xsd (EX-101.SCH) — 1537KB
• mplt-20251231_htm.xml (XML) — 2123KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 39 Item 1B. Unresolved Staff Comments 92 Item 1C. Cybersecurity 92 Item 2.

Properties

Properties 93 Item 3.

Legal Proceedings

Legal Proceedings 93 Item 4. Mine Safety Disclosures 93 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 94 Item 6. Reserved 94 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 95 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 107 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 107 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 107 Item 9A.

Controls and Procedures

Controls and Procedures 107 Item 9B. Other Information 108 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 108 PART III Item 10. Directors, Executive Officers and Corporate Governance 109 Item 11.

Executive Compensation

Executive Compensation 109 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 109 Item 13. Certain Relationships and Related Transactions, and Director Independence 109 Item 14. Principal Accounting Fees and Services 109 PART IV Item 15. Exhibits and Financial Statement Schedules 110 Item 16. Form 10-K Summary 111

Signatures

Signatures 112 Index to Consolidated Financial Statements F- 1 i Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report") contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections titled "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Business" and elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include statements about the following: the timing, progress and results of our preclinical studies and clinical trials of our product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, and the period during which the results of the trials will become available; the timing of any regulatory submissions, initiation of and enrollment in clinical trials and timing of expected clinical results for our product candidates; our ability to identify patie

View Full Filing

View this 10-K filing on SEC EDGAR